Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Reporting

v3.25.1
Segment Reporting
12 Months Ended
Dec. 31, 2024
SEGMENT REPORTING  
SEGMENT REPORTING

NOTE 13  - SEGMENT REPORTING

 

The Company manages the business activities on a consolidated basis and operates in one reportable segment. The Company's reportable segment is microalgae technology.   The segment is research and development operating in both the therapeutic and nutritional sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. As the Company has one reportable segment, sales, cost of sales, research and development, and general and administrative expenses are equal to consolidated results.

 

Financial results for the Company's reportable segment have been prepared using a management approach, which is consistent with the basis and manner in which financial information is evaluated by the Company's Chief Operating Decision Maker ("CODM") in allocating resources and in assessing performance. The Company's CODM is the Chief Executive Officer. The measurement of segment profit or loss that the CODM uses to evaluate the performance of the Company's segment is net income attributable to Zivo Bioscience, Inc.  Financial budgets and actual results used by the CODM to assess performance and allocate resources, as well as strategic decisions related to headcount and other expenditures are reviewed on a consolidated basis. The CODM considers the impact of the significant segment expenses in the table below on net income when deciding where and when to make expenditures.

 

 

 

Year ended December 31,

 

 

 

2024

 

 

2023

 

Total revenue

 

$ 157,220

 

 

$

27,650

 

Total cost of goods sold

 

 

(108,268 )

 

 

(16,040 )

General and administrative

 

 

(10,275,914 )

 

 

(5,897,594 )

Research and development

 

 

(3,134,935 )

 

 

(1,377,028 )

Total interest and other (expense), net

 

 

(22,939 )

 

 

(514,172 )

Net loss

 

$ (13,384,836 )

 

$ (7,777,184 )